Home Newsfeeds HC Wainwright & Co. Downgrades Vascular Biogenics to Neutral

HC Wainwright & Co. Downgrades Vascular Biogenics to Neutral

HC Wainwright & Co. analyst Swayampakula Ramakanth downgrades Vascular Biogenics (NASDAQ:VBLT) from Buy to Neutral.

byBenzinga Newsdesk

July 20, 2022

1 minute read

HC Wainwright & Co. analyst Swayampakula Ramakanth downgrades Vascular Biogenics (NASDAQ:VBLT) from Buy to Neutral.

Your Apple Watch Face Could Soon Change Color Like A Chameleon: What Cupertino’s New Design Patent Reveals

By Sudhanshu Singh

August 23, 4:45 AM

Apple has filed a patent for its wearable that aims to let your Apple Watch's face adapt to the color of external objects like clothing, watch bands, and perhaps even your car.

AAPL

Nokia Analysts Cut Their Forecasts Following Q3 Results

By Lisa Levin

October 20, 2:00 PM

Nokia Corp (NYSE: NOK) reported worse-than-expected third-quarter financial results.

NOK

UBS Initiates Coverage On Delek US Hldgs with Neutral Rating, Announces Price Target of $29

By Benzinga Newsdesk

March 9, 6:25 AM

UBS analyst Manav Gupta initiates coverage on Delek US Hldgs (NYSE:DK) with a Neutral rating and announces Price Target of $29.

Why Is An Earnings Beat Less Likely For BNY Mellon (BK) In Q2?

By Zacks

July 13, 10:42 AM

The Bank of New York Mellon Corporation BK is scheduled to report second-quarter 2022 results on Jul 15, before market open. While its revenues in the to-be-reported quarter are expected to have witnessed a rise on a year-over-year basis, earnings are likely to have declined.

HC Wainwright & Co. Downgrades Vascular Biogenics to Neutral

Related Posts

Your Apple Watch Face Could Soon Change Color Like A Chameleon: What Cupertino’s New Design Patent Reveals

Nokia Analysts Cut Their Forecasts Following Q3 Results

UBS Initiates Coverage On Delek US Hldgs with Neutral Rating, Announces Price Target of $29

Why Is An Earnings Beat Less Likely For BNY Mellon (BK) In Q2?